title: Effects of amiodarone on the circadian pattern of sudden cardiac death (Department of Veterans Affairs Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy).
abstract: Some antiarrhythmic drugs have been shown to influence the circadian pattern of sudden cardiac death (SCD). The effect of chronic amiodarone therapy on this pattern is unknown. This study determines the circadian pattern of deaths in the Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) and compares the distribution of SCD between the amiodarone and the placebo arms of the trial. CHF-STAT was a multicenter trial that determined whether amiodarone reduces mortality in patients with heart failure and asymptomatic ventricular arrhythmias. The time of death was retrospectively analyzed in patients who died from pump failure and SCD. In patients who died suddenly, the circadian pattern of deaths was compared between patients receiving amiodarone and those receiving placebo. In CHF-STAT, 274 patients died during follow-up. The time of death was available in 65 of the 74 patients who died from pump failure, and in 96 of the 139 patients who died suddenly. There was a circadian variation of all SCDs compared with other deaths with a distinct peak during the morning (p = 0.04). A similar morning peak of sudden cardiac death was found in both the amiodarone (n = 42) and the placebo (n = 54) groups, and the overall circadian pattern did not differ between them (p = 0.16). In contrast, death from pump failure occurred equally distributed over time. Thus, SCD occurs predominantly during the morning, whereas death from heart failure does not exhibit a morning peak. Amiodarone does not influence the circadian pattern of SCD.
authors.affiliation: Division of Cardiology, Veterans Administration & Georgetown University Medical Center, Washington, D.C. 20422, USA.
authors.forename: S
authors.initials: S
authors.lastname: Behrens
authors.forename: G
authors.initials: G
authors.lastname: Ney
authors.forename: S G
authors.initials: SG
authors.lastname: Fisher
authors.forename: R D
authors.initials: RD
authors.lastname: Fletcher
authors.forename: M R
authors.initials: MR
authors.lastname: Franz
authors.forename: S N
authors.initials: SN
authors.lastname: Singh
mesh_terms: D000368:Aged; D000638:Amiodarone / Q000494:pharmacology / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002940:Circadian Rhythm / Q000187:drug effects*; D016757:Death, Sudden, Cardiac / Q000517:prevention & control*; D004311:Double-Blind Method; D004452:Echocardiography; D005260:Female; D006333:Heart Failure / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015996:Survival Rate; D017180:Tachycardia, Ventricular / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality*
chemical_list: D000889:Anti-Arrhythmia Agents; D000638:Amiodarone